Health Care & Life Sciences » Biotechnology | e-Therapeutics PLC

e-Therapeutics PLC

e-Therapeutics PLC
Stock Exchange London Stock Exchange
Market Cap
GBP6.85 M
Shares Outstanding
268.69 M
Public Float
199.6 M


17 Blenheim Office Park
Long Hanborough Oxfordshire OX29 8LN
United Kingdom
Employees -
Updated 07/08/2019
e-Therapeutics Plc is a drug discovery and development company, which engages in the provision of evaluation services to investors and pharmaceutical companies. It focuses on the therapeutic immune-oncology, addressing drug resistance in targeted cancer therapies and antivirals. It offers the following variety of preclinical stage assets: ETS2300, telomerase inhibition in anti-cancer; ETS3100, small molecule anti-TNFa; ETS2400, Hedgehog pathway inhibition; and ETS5200, broad spectrum antivirals together with two immuno-oncology checkpoint projects.


View All

Iain Gladstone Ross
Non-Executive Chairman
Raymond Barlow
Chief Executive Officer & Director